Follow The Filings

ONC BeOne Medicines

BeOne Medicines earnings company data as of 4:00 PM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS 2.42 — —
Rev $1.76B — —

Insider trades

Open-market buys and sales by ONC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ONC insider trades
  • None no insider bought on the open market
  • $16.5M sold by 11 insiders outside a trading plan
  • $375M sold by 4 insiders under 10b5-1 plans
  1. Xiaodong Wang Director
    Planned sale
    $11.3M 31,028 shares at $362.97 100% of stake
    Traded Oct 27 Filed Oct 29
  2. Xiaodong Wang Director
    Planned sale
    $10.9M 31,027 shares at $350.99 100% of stake
    Traded Oct 13 Filed Oct 15
  3. Chan Henry Lee SVP, General Counsel
    Planned sale
    $418K 1,115 shares at $375.00 100% of stake
    Traded Sep 30 Filed Oct 2
  4. Xiaodong Wang Director
    Planned sale
    $11.3M 31,028 shares at $364.79 100% of stake
    Traded Sep 28 Filed Sep 30
  5. Xiaodong Wang Director
    Planned sale
    $13.4M 38,287 shares at $349.10 100% of stake
    Traded Sep 8 Filed Sep 10
  6. Titus B. Ball Principal Accounting Officer
    Sale
    $47K 132 shares at $355.86 100% of stake
    Traded Sep 1 Filed Sep 3
  7. Xiaobin Wu COO
    Planned sale
    $106K 280 shares at $380.00 100% of stake
    Traded Aug 25 Filed Aug 27
  8. Chan Henry Lee SVP, General Counsel
    Planned sale
    $960K 2,666 shares at $360.00 100% of stake
    Traded Aug 11 Filed Aug 13
  9. John Oyler CEO
    Planned sale
    $86.5M 240,810 shares at $359.12 100% of stake
    Traded Aug 10–12 Filed Aug 12
  10. Aaron Rosenberg CFO
    Sale
    $362K 1,157 shares at $312.72 100% of stake
    Traded Aug 3 Filed Aug 5
  11. Chan Henry Lee SVP, General Counsel
    Sale
    $338K 1,044 shares at $323.69 100% of stake
    Traded Jul 30 Filed Aug 3
  12. Chan Henry Lee SVP, General Counsel
    Planned sale
    $542K 1,669 shares at $325.00 100% of stake
    Traded Jul 22 Filed Jul 24
  13. John Oyler CEO
    Planned sale
    $34.6M 109,713 shares at $315.28 100% of stake
    Traded Jul 20–21 Filed Jul 22
  14. John Oyler CEO
    Planned sale
    $20.2M 64,628 shares at $312.00 100% of stake
    Traded Jul 17 Filed Jul 17
  15. John Oyler CEO
    Planned sale
    $89.4M 283,154 shares at $315.56 100% of stake
    Traded Jul 15–16 Filed Jul 17

Also filed in the last 12 months, not counted as buying or selling: 51 option exercises, 27 stock grants, and 3 gifts.

SEC filings

Recent issuer filings from EDGAR, 5 shown.

Filed Form Detail Links
SCHEDULE 13D/A —
8-K 2.02,9.01
8-K 2.02,9.01
10-Q
8-K 8.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf